Bristol-Myers Squibb said that Giovanni Caforio, M.D., will become CEO effective May 5. Lamberto Andreotti will become executive chairman of the board. James M. Cornelius will retire. “I want to thank Jim Cornelius for his many years at BMS,” Andreotti said. “I also want to express my excitement that Giovanni has been appointed to succeed me as CEO” … more Separately, BMS reports that that the FDA has approved Evotaz (atazanavir 300 mg and cobicistat 150 mg) tablets in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults … more